ALVAC-HIV and AIDSVAX B/E vaccination induce improved immune responses compared with AIDSVAX B/E vaccination alone

The RV144 phase III vaccine trial demonstrated that ALVAC-HIV and AIDSVAX B/E administration over 6 months resulted in 31% efficacy in preventing HIV acquisition, while administration of AIDSVAX B/E alone in both VAX003 and VAX004 studies failed to show efficacy. In this study, we aimed to understan...

Descripción completa

Detalles Bibliográficos
Autores principales: Costanzo, Margaret C., Paquin-Proulx, Dominic, Schuetz, Alexandra, Akapirat, Siriwat, Shubin, Zhanna, Kim, Dohoon, Wieczorek, Lindsay, Polonis, Victoria R., Trinh, Hung V., Rao, Mangala, Anenia, Hanna, Barrera, Michael D., Boeckelman, Jacob, Nails, Barbara, Thapa, Pallavi, Zemil, Michelle, Sacdalan, Carlo, Kroon, Eugene, Kaewboon, Boot, Tipsuk, Somporn, Jongrakthaitae, Surat, Gurunathan, Sanjay, Sinangil, Faruk, Kim, Jerome H., Robb, Merlin L., Ake, Julie A., O’Connell, Robert J., Pitisutthithum, Punnee, Nitayaphan, Sorachai, Chariyalertsak, Suwat, Eller, Michael A., Phanuphak, Nittaya, Vasan, Sandhya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10243797/
https://www.ncbi.nlm.nih.gov/pubmed/37154156
http://dx.doi.org/10.1172/jci.insight.167664

Ejemplares similares

Ejemplares similares